Restenosis following percutaneous coronary arterial intervention: what should the clinician do in order to identify and treat this complication? Joseph S. Alpert Editor's Commentary Pages: 391 - 392
Antihypertensive drugs and the kidney Mitra K. NadimRenee DuaVito M. Campese OriginalPaper Pages: 403 - 408
Antihypertensive drugs and the heart Joseph A. DiamondRobert A. Phillips OriginalPaper Pages: 409 - 415
Hypertension in black patients: Special issues and considerations Shawna D. Nesbitt OriginalPaper Pages: 416 - 420
Combination drug treatment of hypertension: Have we come full circle? Addison A. Taylor OriginalPaper Pages: 421 - 426
Ezetimibe: A novel cholesterol-lowering agent that highlights novel physiologic pathways Shailendra B. Patel OriginalPaper Pages: 439 - 442
Hypothyroidism and dyslipidemia: Modern concepts and approaches Elizabeth N. Pearce OriginalPaper Pages: 451 - 456
Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story Emma A. Meagher OriginalPaper Pages: 457 - 463
Aggressive diets and lipid responses Claudia PanzerCaroline M. Apovian OriginalPaper Pages: 464 - 473